Posted on April 8, 2010 by Sitemaster
In March this year it was announced that the combination of bevacizumab (Avastin) with docetaxel and prednisone had no benficial impact (in a large Phase III trial) on the overall survival of men with hormone-refractory prostate cancer (HRPC) compared to docetaxel + prednisone alone. There are, naturally, hopes that the outcome might be different if one adds a third drug into the mix. … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: bevacizumab, chemotherapy, docetaxel, hornone-refractory, HRPC, thalidomide | Leave a comment »
Posted on March 12, 2010 by Sitemaster
The pharmaceutical company Roche announced this morning that the combination of bevacizumab (Avastin) with docetaxel and prednisone does not extend the overall survival of men with hormone-refractory prostate cancer (HRPC) compared to docetaxel + prednisone alone. … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: Avastin, bevacizumab, castration-resistant prostate cancer, CRPC, HRPC, survival, trial | Leave a comment »
Posted on June 10, 2009 by Sitemaster
It is well understood that skeletal complications are a crucial factor in the quality of life and the prognosis of patients with hormone-refractory prostate cancer (HRPC); however, their true prevalence and impact on the prognosis remain largely unknown. … READ MORE …
Filed under: Management, Treatment | Tagged: bone pain, complications, hormone-refractoery prostate cancer, HRPC, skeletal | Leave a comment »
Posted on May 6, 2009 by Sitemaster
In today’s new items we identified items dealing with:
- New learnings about radical prostatectomy
- Heated gold nanoparticles as treatment for solid tumors
- A three-drug chemotherapy combination for HRPC … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: docetaxel, estramustine, gold, HRPC, nanoparticles, radical prostatectomy, vinorelbine | Leave a comment »
Posted on January 30, 2009 by Sitemaster
Items covered in this weekend news report include:
- Acrylamide exposure as a potential risk for prostate cancer
- The relative merits of three standard first-line therapies in intermediate risk prostate cancer
- Estramustine + etopside in hormone-refractory prostate cancer (HRPC)
- Bone turnover markers and risk for skeletal-related events in patients receiving zoledronic acid … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: acrylamide, bone turnover markers, brachytherapy, carcinogen, estramustine, etopside, external beam radiation, HRPC, risk, skeletal-related events, SREs, surgery | Leave a comment »
Posted on July 29, 2008 by Sitemaster
Here is Part B of your daily prostate cancer news update. Unless someone announces a cure for prostate cancer we will probably hold any further news until tomorrow! … MORE …
Filed under: Diagnosis, Drugs in development, Management, Treatment | Tagged: AIPC, androgen-independent, cancer, cut-point, hormone refractory, HRPC, laparoscopic, margin, news, open, positive, prostate, prostatectomy, PSA, PSM, radical, somastatin, surgical, update | 1 Comment »
THE "NEW" PROSTATE CANCER INFOLINK 